Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Next-Generation Sequencing (NGS) In Precision Medicine Market Revenue Growth On Track For A 16.9% CAGR Through 2030
The next-generation sequencing (ngs) in precision medicine market size has seen substantial growth in recent years. This market is expected to grow from $6.42 billion in 2025 to $7.52 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 17.2%. The historical expansion of this market can be attributed to the advancement of high-throughput sequencers, increasing awareness of personalized medicine, an increase in genomic research, the expansion of bioinformatics software, and the adoption of precision medicine in clinical trials.
The next-generation sequencing (ngs) in precision medicine market is projected for substantial growth in the coming years. Its value is set to reach $14.05 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 16.9%. This anticipated expansion during the forecast period is due to factors such as improvements in sequencing instrument technology, the incorporation of artificial intelligence into genomics, an increase in cloud-based sequencing offerings, growing partnerships between pharmaceutical and biotechnology firms, and the spread of precision medicine into developing areas. Key developments expected during this period involve AI-driven genomic analysis, cloud-based sequencing platforms, broader adoption of personalized medicine, enhanced automation in sequencing processes, and immediate interpretation of genomic data.
Get A Free Sample Report With In-Depth Market Insights:
Next-Generation Sequencing (NGS) In Precision Medicine Market Growth Drivers: What’s Behind The Acceleration?
The increasing occurrence of genetic disorders is projected to boost the growth of the next-generation sequencing (NGS) in precision medicine market moving forward. Genetic disorders are conditions or illnesses caused by irregularities in an individual’s DNA, which can be inherited or result from mutations. The prevalence of genetic disorders is on the rise as advancements in diagnostic technologies, such as genetic screening and next-generation sequencing, empower doctors to detect cases that were previously missed, leading to a higher reported frequency. Next-generation sequencing in precision medicine is instrumental in identifying genetic mutations, thereby enabling accurate diagnosis, personalized treatment, and prompt intervention for genetic disorders. For instance, in May 2024, data from the National Health Service, a UK-based government department, revealed that approximately 17,000 people in England live with sickle cell disease, an inherited blood disorder, with about 250 new cases diagnosed each year. Hence, the growing incidence of genetic disorders is fueling the expansion of the next-generation sequencing (NGS) in precision medicine market.
Next-Generation Sequencing (NGS) In Precision Medicine Market Segment Analysis: What Are The Core Market Categories?
The next-generation sequencing (ngs) in precision medicine market covered in this report is segmented –
1) By Product And Service: Sequencing Instruments, Consumables And Reagents, Library Preparation Kits, Bioinformatics Software, Next-Generation Sequencing (NGS) Services
2) By Technology: Whole Genome Sequencing (WGS), Whole Exome Sequencing (Wes), Targeted Sequencing, Ribonucleic Acid (RNA) Sequencing, Single-Cell Sequencing
3) By Application: Oncology, Infectious Disease, Rare And Inherited Disorders, Prenatal And Reproductive Health, Pharmacogenomics
4) By End Use: Hospitals And Clinics, Academic And Research Institutions, Biopharmaceutical Companies, Diagnostic Laboratories, Contract Research Organizations (CROs)
Subsegments:
1) By Sequencing Instruments: Benchtop Sequencers, High Throughput Sequencers
2) By Consumables And Reagents: Sequencing Reagents, Sequencing Chips, Flow Cells, Sample Preparation Reagents
3) By Library Preparation Kits: Deoxyribonucleic Acid (DNA) Library Preparation Kits, Ribonucleic Acid (RNA) Library Preparation Kits, Whole Genome Amplification Kits, Target Enrichment Kits
4) By Bioinformatics Software: Data Analysis Software, Data Management Software, Sequence Alignment Software, Variant Calling Software
5) By Next-Generation Sequencing Services: Whole Genome Sequencing Services, Whole Exome Sequencing Services, Targeted Sequencing Services, Ribonucleic Acid (RNA) Sequencing Services, Epigenomic Sequencing Services
Next-Generation Sequencing (NGS) In Precision Medicine Market Trends: What’s Defining The Industry’s Next Phase?
Major companies operating in the next-generation sequencing (NGS) in precision medicine market are focusing on developing innovative solutions, such as multimodal DNA and RNA library kits, to enhance the efficiency and accuracy of genomic analyses. A multimodal DNA and RNA library kit is a laboratory kit that enables the simultaneous preparation of sequencing libraries from both DNA and RNA in a single workflow, allowing for comprehensive analysis of a sample’s genome and transcriptome. For instance, in May 2024, Qiagen N.V., a Germany-based provider of sample and assay technologies for molecular diagnostics, launched the QIAseq Multimodal DNA and RNA Library Kit. This next-generation sequencing solution facilitates multiomic studies and advances precision medicine by enabling streamlined DNA and RNA library preparation from a single sample. The kit supports whole genome and whole transcriptome sequencing and downstream target enrichment, facilitating multiomic studies by combining optimized chemistry for DNA and RNA simultaneously. It reduces the need for large sample amounts and labor-intensive procedures found in traditional separate DNA and RNA workflows. By enhancing efficiency in multiomic research, this kit advances precision medicine through better biomarker discovery and disease understanding, particularly in cancer research.
Next-Generation Sequencing (NGS) In Precision Medicine Market Key Players Shaping Industry Direction
Major companies operating in the next-generation sequencing (ngs) in precision medicine market are Thermo Fisher Scientific Inc., Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., Exact Sciences Corporation, QIAGEN N.V., Natera Inc., Tempus Labs Inc., 10x Genomics Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Caris Life Sciences Inc., Fulgent Genetics Inc., Twist Bioscience Corporation, Pacific Biosciences of California Inc., Macrogen Inc., Ultima Genomics Inc., Personalis Inc., Element Biosciences Inc., Genomenon Inc., Strand Life Sciences Pvt. Ltd., Singular Genomics Systems Inc.
View The Full Next-Generation Sequencing (NGS) In Precision Medicine Market Report:
Next-Generation Sequencing (NGS) In Precision Medicine Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the next-generation sequencing (NGS) in precision medicine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation sequencing (ngs) in precision medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model